Zacks Research Has Bullish Forecast for CRL Q2 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Stock analysts at Zacks Research boosted their Q2 2026 earnings per share estimates for Charles River Laboratories International in a research report issued to clients and investors on Wednesday, March 11th. Zacks Research analyst Team now anticipates that the medical research company will earn $2.85 per share for the quarter, up from their previous estimate of $2.74. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q3 2026 earnings at $2.86 EPS, FY2026 earnings at $10.78 EPS, Q1 2027 earnings at $2.62 EPS, Q2 2027 earnings at $2.65 EPS, Q3 2027 earnings at $3.02 EPS, FY2027 earnings at $11.62 EPS and FY2028 earnings at $12.12 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The firm had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. During the same period in the previous year, the firm earned $2.66 EPS. The business’s revenue for the quarter was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS.

Other equities research analysts also recently issued reports about the stock. TD Cowen reduced their price objective on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, December 15th. Mizuho reduced their target price on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Friday, February 20th. Robert W. Baird set a $193.00 price target on Charles River Laboratories International in a research report on Thursday, February 19th. Finally, UBS Group lifted their price target on Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Ten investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of “Moderate Buy” and an average target price of $203.57.

Charles River Laboratories International Stock Down 9.9%

CRL opened at $152.22 on Thursday. Charles River Laboratories International has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The firm has a market capitalization of $7.49 billion, a P/E ratio of -51.43, a PEG ratio of 2.89 and a beta of 1.64. The company’s 50-day moving average is $192.53 and its 200 day moving average is $180.94. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02.

Institutional Investors Weigh In On Charles River Laboratories International

Several large investors have recently modified their holdings of the stock. Eos Management L.P. bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth approximately $839,000. Corient Private Wealth LLC grew its holdings in Charles River Laboratories International by 68.5% during the fourth quarter. Corient Private Wealth LLC now owns 17,628 shares of the medical research company’s stock valued at $3,516,000 after purchasing an additional 7,166 shares during the period. SHP Wealth Management purchased a new stake in Charles River Laboratories International in the fourth quarter worth $85,000. Kera Capital Partners Inc. increased its position in Charles River Laboratories International by 4.5% in the fourth quarter. Kera Capital Partners Inc. now owns 2,511 shares of the medical research company’s stock worth $529,000 after buying an additional 108 shares during the last quarter. Finally, Compound Planning Inc. raised its stake in shares of Charles River Laboratories International by 19.6% in the fourth quarter. Compound Planning Inc. now owns 1,668 shares of the medical research company’s stock valued at $333,000 after buying an additional 273 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.